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Abstract
Background: Escherichia coli is a major human pathogen, both in community and healthcare settings. To date
however, relatively few studies have defined the population burden of E. coli bloodstream infections. Such
information is important in informing strategies around treatment and prevention of these serious infections.
Against this background, we performed a retrospective, population-based observational study of all cases of E. coli
bacteremia in patients presenting to our hospital between January 2005 and December 2011.
Methods: Auckland District Health Board is a tertiary-level, university-affiliated institution serving a population of
approximately 500,000, within a larger metropolitan population of 1.4 million. We identified all patients with an
episode of bloodstream infection due to E. coli over the study period. A unique episode was defined as the first
positive E. coli blood culture taken from the same patient within a thirty-day period. Standard definitions were used
to classify episodes into community- or healthcare-associated E. coli bacteremia. Demographic information was
obtained for all patients, including: age; gender; ethnicity; length of stay (days); requirement for intensive care
admission and all-cause, in-patient mortality.
Results: A total of 1507 patients had a unique episode of E. coli bacteremia over the study period. The overall
average annual incidence of E. coli bacteremia was 52 per 100,000 population, and was highest in the under one
year and over 65-year age groups. When stratified by ethnicity, rates were highest in Pacific Peoples and Māori
(83 and 62 per 100,000 population respectively). The incidence of community-onset E. coli bacteremia increased
significantly over the study period. The overall in-hospital mortality rate was 9% (135/1507), and was significantly
higher in patients who had a hospital-onset E. coli bacteremia.
Conclusions: Our work provides valuable baseline data on the incidence of E. coli bacteremia in our locale. The
incidence was higher that that described from other developed countries, with significant demographic variation,
most notably in ethnic-specific incidence rates. Future work should assess the possible reasons for this disparity.
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Background
Escherichia coli is a major human pathogen, and infec-
tions caused by E. coli result in significant morbidity and
mortality [1]. Although most commonly associated with
uncomplicated urinary tract infections, extraintestinal
strains of E. coli can also cause a wide variety of serious in-
fections, including meningitis, pneumonia and bacteremia
[1]. Previous studies have consistently ranked E. coli as the
most common cause of community-onset bacteremia, and
a major causative pathogen in nosocomial bacteremia [2-6].
Over the past decade, several countries have described an
increase in the incidence of E. coli bloodstream infections
(EC-BSI) [7,8]. In the United Kingdom, this phenomenon
has resulted in the introduction of mandatory surveillance
of EC-BSI in order to investigate the possible factors
underlying the increase in these serious infections [8,9].
Over the past two decades, treatment of EC-BSI has
become increasingly complicated by the emergence of
antimicrobial-resistant E. coli strains. In particular, acquired
resistance due to genes encoding extended-spectrum beta-
lactamases (ESBLs) and carbapenemases poses a significant
therapeutic challenge, and bloodstream infections with
these resistant organisms have been associated with adverse
clinical and economic consequences [10,11].
However, despite the significant morbidity and mortal-
ity associated with EC-BSI, relatively few studies have
attempted to define the population burden of these
important infections [5,12]. In addition, although
sociodemographic disparities have been described for
other major causes of bloodstream infections such as
Staphylococcus aureus [13] and Streptococcus pneumoniae
[14], little data exists on the potential demographic vari-
ation in episodes of EC-BSI. Such population-based
epidemiological information is important in informing
strategies around treatment and prevention of these serious
infections.
Accordingly, we sought to assess the incidence,
antimicrobial-resistance trends and outcomes of EC-BSI
in patients presenting to our hospital between January
2005 and December 2011, with particular regard to any
variation in demographic characteristics. In addition, we
sought to describe any demographic variation in the
incidence of community-associated (CA) vs. healthcare-
associated (HCA) EC-BSI in our locale.
Methods
Setting and study design
Auckland District Health Board (ADHB) is a tertiary-
level, university-affiliated institution which exclusively
serves a population of approximately 500,000, within a
larger metropolitan region of 1.4 million. Auckland is
the largest city in New Zealand, and has an ethnically di-
verse population, consisting of the following major
population groups: European (52%); Asian (29%), Pacific
Island peoples (11%); Māori (indigenous New Zealander,
8%) and other ethnicities (2%) [15].
We performed a retrospective cross-sectional study of
all patients at ADHB with EC-BSI between January 2005
and December 2011. Cases of EC-BSI were identified from
the laboratory database in the Department of Clinical
Microbiology, Auckland City Hospital, New Zealand. A
unique episode was defined as the first positive E. coli
blood culture taken from the same patient within a thirty-
day period.
Data collection and definitions
Using information extracted from the hospital administra-
tive database, the following demographic information was
obtained for each patient: age, gender, ethnicity, domicile,
and number of previous hospitalizations in the preceding
year. In addition, we also extracted all hospital discharge
diagnoses related to each episode of EC-BSI, coded using
the International Classification of Diseases, Tenth Edition,
Clinical Modification (ICD-10-CM) codes [16].
In keeping with previous methodology [17], cases were
described as community-associated EC-BSI (CA EC-BSI)
if E. coli was isolated from the bloodstream of a patient
within 48 hours of hospital admission who: (i) had no
history of hospitalization or surgery in the preceding
calendar year, and (ii) did not reside in a long-term care
facility (LTCF), and (iii) did not have any prior or
current ICD-10-CM discharge diagnoses relating to
hemodialysis. Conversely, cases were described as
healthcare-associated EC-BSI (HCA EC-BSI) if one or
more of these risk factors were documented. Healthcare-
associated cases were further described as hospital-onset
(HCA-HO) or community-onset (HCA-CO) depending
on whether the specimen was taken > 48 hours or ≤
48 hours respectively, following hospital admission.
Population denominator information was obtained
from the 2006 New Zealand census, and from projected
population data for the Auckland region [15]. For ana-
lysis, ethnicity was grouped into four major ethnic
groupings: European, Māori, Pacific Peoples and Asian/
other ethnicities.
The following clinical outcome measures were obtained
for all patients: length of hospital stay (days), requirement
for intensive care unit admission, and all-cause in-patient
hospital mortality. For all patients who had hospital-onset
EC-BSI, the time (in days) from admission to first positive
blood culture was calculated.
Microbiological analysis
All E. coli isolates were identified using the RapID One
system (Remel Diagnostics). Susceptibility testing was
performed using agar dilution in keeping with Clinical
and Laboratory Standards (CLSI) recommendations for
the following antimicrobials: amoxicillin, amoxicillin-
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clavulanate, ticarcillin-clavulanate, cephalothin, cefuroxime,
ceftazidime, ceftriaxone, gentamicin, amikacin, trimethoprim-
sulphamethoxazole, ciprofloxacin and meropenem [18].
Isolates testing as intermediate were classified as resistant.
ESBL and / or carbapenemase production was detected
according to CLSI recommendations [18]. An isolate was
classified as multidrug-resistant (MDR) if it displayed
resistance to at least one representative of ≥ 3 classes of
antimicrobial agents, as previously described [19].
Statistical analysis
Categorical variables were compared using either the χ2
or Fisher’s exact test as appropriate. Non-parametric
data were expressed as median values with interquartile ra-
ges (IQR), and were compared using the Mann–Whitney
U test or Kruskal-Wallis analysis of variance (ANOVA)
test. Incidence rates were calculated per 100,000 popula-
tion, and were stratified according to age, gender and eth-
nicity. A Poisson log-linear regression model was used to
assess trends in incidence rates over time using log popula-
tion denominator data as the offset variable. All statistical
analysis was performed using GraphPad Prism (Version
5.02) or STATA (Version 11) and a two-tailed P value
of < 0.05 was considered significant.
Ethics
The Auckland District Health Board, New Zealand,
granted institutional approval for this study.
Results
Patients and incidence rates of E. coli bacteremia
A total of 1507 patients had an episode of EC-BSI over
the study period. The overall average annual incidence
of EC-BSI was 52 per 100,000 population, and increased
from 42 to 60 per 100,000 population over the study
period (Figure 1). When stratified by age (Figure 2A),
the incidence was highest in the under one and over
75 year age brackets (149 and 310 per 100,000 popula-
tion respectively), and when stratified by ethnicity
(Figure 2B), the incidence was highest in Māori and
Pacific Peoples (83 and 62 per 100,000 population re-
spectively). Of the 1507 episodes of EC-BSI, 510/1507
(34%) were classified as CA EC-BSI, 608/1507 (40%)
were HCA-CO EC-BSI, and 389/1507 (26%) were
HCA-HO EC-BSI (Figure 3). The incidences of HCA-
CO and HCA-HO EC-BSI did not increase signifi-
cantly over the study period; however, the incidence
of CA EC-BSI increased significantly from 13 per
100,000 to 22 per 100,000 population (P < 0.001).
Demographic characteristics and clinical outcomes
Full demographic data were available for 1467 patients
with EC-BSI (Table 1). Of these 1467 patients, 806
(54.9%) patients were of European ethnicity, 288 (19.6%)
were Pacific Peoples, 220 (15.0%) were Asian, 133 (9.1%)
were Māori and 20 (1.4%) were of other ethnicities. The
median age of the patients was 63 years (IQR 45 –
77 years), and was significantly lower in patients with
HCA-HO infections (median 58 years; IQR 35 –
75 years) compared to patients with HCA-CO infections
(median 65 years; IQR 47 – 79 years) or CA infections
(median 63 years; IQR 47 – 74 years) (Table 1). Overall,
678 / 1507 (55%) patients were female; however, patients
with HCA-HO infections were significantly more likely
to be male than patients with CA or HCA-CO infections
(Table 1). The median length of stay was 7 days (IQR
4 – 16 days), and was significantly higher in those
patients with HCA-HO infections (Table 1). Overall,
216 / 1507 (14%) of patients with EC-BSI had an ICU
admission, and the aggregate in-hospital mortality rate
was 9%. When compared to patients with CA and
HCA-CO infections, patients with HCA-HO infec-
tions were significantly more likely to have an ICU
admission and were significantly more likely to die
during their hospital admission (Table 1). The median
duration between hospital admission and first EC-BSI
in patients with HCA-HO infections was 11.4 days
(IQR 7.1 – 15.2 days).
Rates and trends of antimicrobial resistance in Escherichia
coli bloodstream isolates
Antimicrobial susceptibility test results were available
for 1505/1507 (99%) isolates. The overall rates of resist-
ance were: amoxycillin, 61% (911/1505 isolates); cepha-
lothin, 48% (724/1505); cefuroxime, 9% (132/1505);
ceftriaxone, 4% (60/1505); aztreonam, 4% (57/1505);
amoxycillin-clavulanate, 24% (356/1505); ticarcillin-
clavulanate, 30%, 455/1505; gentamicin, 8% (113/1505);
amikacin, 0.2% (3/1505); trimethoprim-sulfamethoxazole,
35% (532/1505), and ciprofloxacin, 10% (157/1505).
Rates of resistance to any of the tested antimicrobials
did not increase significantly over the study period
(Figure 4). ESBL production was detected in 5.6%
(84/1505) of isolates tested. No carbapenemase-
producing E. coli bloodstream isolates were detected
over the study period. The prevalence of ESBL-
producing E. coli was significantly higher in HCA-HO
infections when compared to HCA-CO EC-BSI infec-
tions (P = 0.04) or CA EC-BSI infections (P = 0.04). In
addition, MDR - E. coli isolates were significantly less
common in CA EC-BSI infections when compared to
HCA-CO infections (P = 0.003) or HCA-HO infec-
tions (P = 0.07).
Discussion
In this study, we assessed the incidence and clinical out-
comes of EC-BSI in our locale, with a particular focus
on possible sociodemographic variation. In addition to





























































































Figure 2 Incidence of Escherichia coli bloodstream infection Auckland District Health Board, New Zealand, 2005 – 2011, stratified by














































Figure 1 Incidence of Escherichia coli bloodstream infection, Auckland District Health Board, New Zealand, 2005–2011.
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further highlighting the demographic differences be-
tween community and nosocomial EC-BSI, we also
found notable differences across both age and ethnic
groups. These findings have implications for the follow-
ing reasons.
Firstly, our study provides valuable baseline data on
the incidence and burden of EC-BSI in New Zealand. By
utilizing a population-based approach, our data can be
compared to studies in other settings that have assessed
the population burden of these serious infections. We
found that the overall incidence of EC-BSI in our setting
(52 per 100,000 population) was higher than that
reported from studies in similar developed countries.
For example, Kennedy et al. reported an incidence of
EC-BSI of 28 per 100,000 population per year in
Canberra, Australia [12], and a recent Finnish study ob-
served an average annual rate of 44 per 100,000 popula-
tion between 2004 and 2007 [20]. The reasons for the
higher observed rate of EC-BSI in our locale are unclear;
however the incidence of other specific infectious dis-
eases are also notably higher in New Zealand compared
to other settings, including skin and soft tissue infections
[21], campylobacteriosis [22] and meningococcal disease
[23]. Similar to other studies [5,12,24], we also observed
an age-related difference in the incidence of EC-BSI,
with the highest incidence in the very young and elderly























63 (45 – 77) 63 (47 – 74) 65 (47–79) 58 (35–75) 0.05 0.01 < 0.001




7 (4–16) 5 (3 – 8) 6 (4 – 10) 24 (14 – 40) < 0.001 < 0.001 <0.001
ICU admission b 216 (14) 56 (11) 50 (8) 110 (28) 0.31 < 0.001 < 0.001
In-hospital mortality b 135 (9) 21 (4) 57 (9) 57 (15) < 0.001 < 0.001 0.01
Isolate characteristics
ESBL phenotype b, c 66 (4.4) 24 (5) 30 (5) 32 (8.5) 0.89 0.04 0.04
MDR phenotype b 609 (40) 180 (35) 268 (44) 161 (41) 0.003 0.07 0.43
a P value calculated using Mann Whitney U test.
b P value calculated using χ2 test.











































Figure 3 Incidence of Escherichia coli bloodstream infection Auckland District Health Board, New Zealand, 2005 – 2011, stratified by
place of acquisition.
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age groups. Unexpectedly, we found a difference in the
incidence of EC-BSI across ethnicities, with rates highest
in Pacific Peoples and Māori (83 and 62 per 100,000
population respectively). To our knowledge, our study
represents the first to describe ethnicity-related differ-
ences in the incidence of EC-BSI, and is consistent with
previous studies in our setting describing ethnic vari-
ation in other infectious diseases [25-27]. It is unclear
why the incidence of EC-BSI is highest in these specific
ethnic groups; however, possible reasons include barriers
in accessing healthcare resulting in delayed presentation
to hospital [28,29], and the higher incidence of medical
co-morbidities in these populations, notably diabetes
mellitus [30].
Secondly, by stratifying EC-BSI into place of acquisi-
tion, we were able to detect differences in both the inci-
dence and demographics of community vs. healthcare-
associated infections. Approximately one-third of cases
occurred in patients with no prior healthcare exposure
and were therefore considered to represent true CA
EC-BSI. Although the incidence of HCA EC-BSI did
not increase over the study period, the incidence of
CA E. coli bacteremia rose significantly (P < 0.001).
Increasing rates of CA EC-BSI have been also de-
scribed in other countries [7,8]; suggested reasons for
the increase in these settings include climatic factors
and rising rates of antimicrobial resistance [7,8]. Similar to
other studies [6,24], we found that the vast majority (74%)
of cases of EC-BSI in our setting originated in the
community. Interestingly however, most of these episodes
occurred in patients with prior healthcare exposure, and
were classified as HCA-CO EC-BSI. This finding may
reflect changes in healthcare delivery, with increasingly
complex medical treatments and procedures being deliv-
ered in a community setting. Recently, it has been sug-
gested that the subgroup of HCA-CO BSI represents a
distinct epidemiological entity, with overlapping demo-
graphic features of both community and nosocomial
bacteremia [31]. In keeping with this suggestion, we also
observed notable differences between the three acquisition
categories. For example, characteristics of patients with
HCA-CO EC-BSI were similar to CA EC-BSI with regards
to age and gender, but had intermediate features between
CA and HCA-HO EC BSI regarding clinical outcomes,
such as length of stay and in-hospital mortality. In
addition, we also observed differences in antimicrobial re-
sistance phenotype between the three categories, such that
the ESBL and MDR phenotypes were commoner in pa-
tients with HCA-HO infections, and the MDR phenotype
was less common in CA EC-BSI infections. This finding is
consistent with other studies describing healthcare expos-
ure as a risk factor for these specific antimicrobial resist-
ance profiles [32,33].
Finally, unlike other studies [7,8] we did not observe a
significant increase in the rates of antimicrobial resist-
ance amongst our E. coli bloodstream isolates over the
study period. In general, rates of antimicrobial resistance
are low in New Zealand compared to other settings.
In particular, resistance rates for fluoroquinolones,
aminoglycosides and third generation cephalosporins
were lower than rates reported from studies in other coun-
tries [7]. Although we did not detect any carbapenemase-
producing isolates in our study, these organisms have been





























Figure 4 Rates of antimicrobial resistance among Escherichia coli bloodstream isolates, Auckland District Health Board, New
Zealand, 2005–2011.
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travellers returning from areas with a reported high preva-
lence of highly resistant Enterobacteriaceae [34,35].
There were a number of limitations with our study.
Most notably, our retrospective approach meant we were
unable to collect information on medical co-morbidities
and the source of EC-BSI. In particular, identification of
the focus of infection would have allowed us to identify
potentially modifiable risk factors for preventing EC-BSI.
For example, a previous study in our setting found that
20% of CA EC-BSI in males was secondary to recent pros-
tate biopsy [36]. A further limitation was our use of in-
patient mortality as an outcome measure. This limited our
comparison with other studies of EC-BSI that have pre-
dominantly assessed mortality rates at either seven days
[12] or thirty days [2].
Conclusions
In summary, our work provides valuable baseline data
on the incidence and burden of EC-BSI in our locale.
The incidence of EC-BSI was higher that that described
from other developed countries, with significant demo-
graphic variation, most notably in ethnic-specific inci-
dence rates. Future work in our setting should assess the
possible reasons for these differences, in addition to
identifying potentially modifiable risk factors for these
serious infections.
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